Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An antigen was detected by counterelectrophoresis in serum samples from six of seven chimpanzees during the acute phase of experimentally induced non-A, non-B hepatitis using antiserum from a chimpanzee convalescent from human non-A, non-B hepatitis. This antigen could not be detected in 35 preinoculation serum samples from these chimpanzees, or in 94 weekly bleedings from three chimpanzees with hepatitis A and three chimpanzees with hepatitis B. The antigen was detected in serum samples obtained from three humans with chronic non-A, non-B hepatitis whose blood had transmitted non-A, non-B hepatitis to other humans (including a nurse by accidental needlestick) and to chimpanzees by experimental inoculation. In addition, the antigen was detected in serum obtained retrospectively from 11 to 31 former blood donors whose blood had transmitted posttransfusion non-A, non-B hepatitis several years previously to recipients of a single unit of their blood. Antibody to this antigen was detected in convalescent serum samples from all seven chimpanzees studied, in convalescent serum from the nurse infected by accidental needlestick, and in serum from a hemodialysis patient convalescent from non-A, non-B hepatitis.
 ...
PMID:Detection of an antigen-antibody system in serum associated with human non-A, non-B hepatitis. 11 28

Hepatitis B virus-like particles (including DANE particles) with DNA polymerase activity but negative for HBs Ag have been identified in NON-A, NON-B hepatitis sera positive for HC Ag. Although specifically associated with the particles, HC Ag is not a surface antigen of the hepatitis C virus identified here for the first time. The relationship of this agent with HBV seems obvious, and deserves further study.
 ...
PMID:[Identification of a virus similar to hepatitis B virus in non-A non-B hepatitis]. 12 Jul 82

Sera from 521 residents of an institution for the mentally retarded near Helsinki, Finland were examined by a hemagglutination assay to determine the distribution and titers of antibodies to hepatitis B surface antigen (anti-HBs). 36.1% were found to contain anti-HBs. Factors were identified which are related to the presence or absence of anti-HBs in this population. A documented past history of hepatitis, living in "asocial" wards in which at least one HBsAg carrier was present, long institutionalization (is greater than 10 yrs.), admission to the institution between ages 5 and 19, a present age between 20 and 39, and being male were associated with the presence of anti-HBs. 43.5% of the males but only 22.2% of the females had antibody. Down's syndrome patients had lower titers but not lower frequencies of anti-HBs than the non Down's patients.
 ...
PMID:Antibody to hepatitis B antigen (Australia antigen) among residents of a Finnish institution for the mentally retarded. 12 6

The clinical importance of the hepatitis B antigen (HBsAg) is based mainly on the differentiation between different courses of inflammatory liver diseases and/or nonvirus induced diseases of the liver. Epidemiologic studies have shown that beside a parenteral inoculation there is a possibility of a non-parenteral inoculation. Furthermore, there is evidence that the sporadic hepatitis is more commonly hepatitis B. Epidemiologic investigations revealed that clinically healthy HBsAg carriers, the "carrier" status in immunodeficiency syndromes and the natural circulation of the hepatitis B virus are of major interest. The demonstration of HBsAg enables us to characterize some diseases which show associations to hepatitis B virus, but where the pathogenic role of HBsAg/Ab immunocomplexes is questionable. Furthermore, it was possible by the detection of HBsAg to establish newer therapeutic and preventive interventions of virus B hepatitis.
 ...
PMID:[Clinical importance of hepatitis B antigen (author's transl)]. 12 47

Subtyping of hepatitis B antigen (HBs Ag) in patients with acute hepatitis B revealed subtype ay in 75 percent while subtype ad was much more common in chronic hepatitis B infections: 81 percent of HBs Ag positive blood donors and 76 percent of patients with HBs Ag positive chronic aggressive hepatitis revealed subtype ad. In contrast to blood donors and chronic hepatitis patients, a change of the prevalent subtype was noted in acute hepatitis patients between 1970 and 1974. Before May 1972, subtype ad was found in 67 percent of patients, whereas later subtype ay dominated in 93 percent. An unequal distribution of subtypes between acute and chronic forms of hepatitis B infections has been explained by differences in the virulence of virus strains. Our results suggest that the higher prevalence of subtype ad in longterm carriers may be due to infection during an earlier time when subtype ad was also common in acute infections. The change of the prevalent subtype in acute infections may be attributed to differences in contagiosity rather than differences in virulence of virus strains.
 ...
PMID:[Change of the prevalent subtype of hepatitis B antigen in acute hepatitis B infections (author's transl)]. 12 76

Data obtained concerning Hepatitis B as a possible couse of Down's syndrome, neonatal hepatitis, and the occurrence of Hepatitis A and B in institutionalized Down's syndrome and matched non-Down's syndrome retarded patients was summarized. The results of our studies indicated that Hepatitis B infection during pregnancy was not related to the genetic changes associated with Down's syndrome. It was further indicated that in institutionalized patients the incidence of Hepatitis B infection in both Down's syndrome and other mentally retarded patients was similar. Within the institition we studied, the incidence of Hepatitis B varied among wards. This ward variation seemed to be related to age at time of institutionalization and degree of mental retardation. Those patients with most retardation and those institutionalized at an early age were placed on wards with highest incidence of Hepatitis B antigenemia.
 ...
PMID:Hepatitis and Down's syndrome. 12 5

Hepatitis B (HbsAg) surface antigen has been detected in the serum of patients with a variety of diseases and immune complexes of this antigen and antibody have been implicated in tissue damage to various organs. Previously we have demonstrated that serum cryoproteins occur in a variety of immune complex disorders and represent pathogenic complexes of antigen and specific antibody. Sera from patients with acute HbsAg positive hepatitis, chronic hepatitis B antigenemia, acute and chronic HbsAg negative hepatitis, as well as a variety HbsAg negative miscellaneous liver diseases and normals were studied for the presence and nature of cryoproteins. Cryoproteins were detected in a large number of patients with acute and chronic HbsAg positive hepatitis and chronic HbsAg carriers. The quantity of these cold insoluble precipitates was highest in acute hepatitis. Cryoproteins were detected with much less frequency in HbsAg negative patients and were not found in normals. The precipitates in HbsAg patients contained either HbsAg, anti-HBsAg or both, along with immunoglobulins and occasionally complement and rheumatoid factor. The cryoproteins in these patients had biological properties attributable to immune complexes and several of the patients had clinical manifestations of acute or chronic serum sickness. Cryoproteins from HbsAg negative patients did not contain HbsAg or antibody to HbsAg and did not have biologic properties of immune complexes. In HbsAg positive patients HbsAg and antibody to HbsAg were concentrated in the cryoprecipitate. The preliminary studies suggest that investigation on cryoproteins in hepatitis may be of clinical and immunopathogenic value.
 ...
PMID:The nature and incidence of cryoproteins in hepatitis B antigen (HbsAg) positive patients. 13 Jun 50

Hepatitis B core antigen (HBc Ag) and hepatitis B surface antigen (HBs Ag) were detected in the liver tissue of a patient with chronic aggressive hepatitis by the immunofluorescent complement technique. The presence of anti-HBc was examined by the same method in 67 human sera previously tested for HBs Ag, anti-HBs and s-GPT levels. HBc Ag was localized mainly in the nucleus and sometimes in the cytoplasm of the hepatic cells. HBs Ag was found only in the cytoplasm. The focal area of HBc Ag positive hepatic cells seemed to correspond to the HBs Ag positive cells. Double staining demonstrated the simultaneous presence of HBs Ag and HBc Ag in individual cells. Anti-HBc positive serum was found in 46 (68.7%) cases. Forty-eight (71.6%) indicated a combination of HBs Ag and anti-HBc.
 ...
PMID:Detection of liver HBc antigen and its antibody in sera from viral hepatitis by the immunofluorescent complement technique. 13 80

Institutionalized patients with Down syndrome and matched controls with other causes of mental retardation were tested by immune adherence hemagglutination for the presence of antibody to hepatitis A antigen (anti-HA). Altogether 75.1% (175 of 233) exhibited presence of anti-HA, with no differences by sex or age. Patients reactive for hepatitis B surface antigen (HBsAg) or its antibody (anti-HBs) were reactive for anti-HA significantly more frequently than those with a negative reaction for these markers. In contrast to serologic markers of hepatitis type B, prevalence of anti-HA does not depend on the cause of mental retardation or on the age at primary infection. The rate of anti-HA positivity was found to be closely correlated with duration of institutionalization. The study confirmed that many closed institutions for the mentally retarded are hyperendemic for hepatitis type A and that formation of anti-HA is not greatly affected by either immune deficiency or immune immaturity.
 ...
PMID:Antibody to hepatitis A antigen in institutionalized mentally retarded patients. 13 79

The present paper concerns the following more important problems: -- hepatitis virus type B: morphology, antigenic structure, virus -- host interaction; -- first attempts at vaccination in hepatitis B; -- vaccines prepared from purified viral subunits; -- study of the pathogenicity and population selected as candidates for testing the efficiency of the vaccine.
 ...
PMID:[Prospects in the specific prevention of type B viral hepatitis]. 14 Oct 80


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>